Klaus Wagner, M.D., Ph.D.

Dr. Wagner has over 20 years of experience in cancer research and clinical drug development, most recently as Executive Vice President and Chief Medical Officer at Inhibrx, Inc. At Inhibrx, Dr. Wagner built and led an integrated clinical development organization that was responsible for advancing four therapeutic candidates, including three oncology programs from pre-IND into the clinic. Dr. Wagner previously served as Medical Oncologist at Banner MD Anderson Cancer Center and as Adjunct Assistant Professor, Department of Thoracic, Head & Neck Medical Oncology at MD Anderson Cancer Center, where he led molecularly targeted therapy and cancer immunotherapy trials in non-small cell lung cancer as a local principal investigator. Before that, Dr. Wagner trained at MD Anderson Cancer Center as a fellow in Medical Oncology. Prior to that Dr. Wagner’s scientific work at Genentech, Inc. and the Genomics Institute of the Novartis Research Foundation focused on cancer drug discovery and predictive biomarker development. Dr. Wagner received the highest academic honors and was a scholar of the German National Academic Scholarship Foundation. Dr. Wagner received his M.D. and Ph.D. from the Friedrich-Alexander University of Erlangen in Germany.